Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP5K1C | O60331 | 20/20 | 0.85 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.85 |
| ▸ | PIP5K1B | O14986 | 4/20 | 0.70 |
| ▸ | PIP5K1A | Q99755 | 4/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.70 |
| ▸ | PI4KA | P42356 | 3/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.70 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530015 | 0.95 | PIP5K1C (0.85) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6504296 | 0.91 | PIP5K1C (0.79) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6503198 | 0.90 | PIP5K1C (0.79) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6504937 | 0.89 | PIP5K1C (0.77) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6533225 | 0.88 | PIP5K1C (0.74) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6501419 | 0.87 | PIP5K1C (1.00) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6501794 | 0.87 | PIP5K1C (0.73) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6507850 | 0.86 | PIP5K1C (0.84) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6502234 | 0.85 | PIP5K1C (0.83) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD | |
| SCHEMBL6531186 | 0.85 | PIP5K1C (0.70) | PIP5K1CPIK3CAPIP5K1BPIP5K1APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005003123-A1 | NOVEL PYRIDINE DERIVATIVES AS JNK SPECIFIC INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | WO | claimed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| WO-2005003123-A1 | NOVEL PYRIDINE DERIVATIVES AS JNK SPECIFIC INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | PIP5K1C 1894/4885PIK3CA 979/4885PIP5K1B 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.